MX2016002581A - Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5. - Google Patents

Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.

Info

Publication number
MX2016002581A
MX2016002581A MX2016002581A MX2016002581A MX2016002581A MX 2016002581 A MX2016002581 A MX 2016002581A MX 2016002581 A MX2016002581 A MX 2016002581A MX 2016002581 A MX2016002581 A MX 2016002581A MX 2016002581 A MX2016002581 A MX 2016002581A
Authority
MX
Mexico
Prior art keywords
pds5
inhibitor
pharmaceutical formulations
novel pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
MX2016002581A
Other languages
English (en)
Inventor
Lad Vinaykumar
Patel Keyur
Doshi Chetan
Sherman Barry
Original Assignee
Apotex Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59684801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016002581(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apotex Tech Inc filed Critical Apotex Tech Inc
Priority to MX2016002581A priority Critical patent/MX2016002581A/es
Priority to PCT/IB2017/000242 priority patent/WO2017144973A2/es
Publication of MX2016002581A publication Critical patent/MX2016002581A/es
Priority to CL2018002441A priority patent/CL2018002441A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/305—Mercury compounds
    • A61K31/31—Mercury compounds containing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para el tratamiento curativo o profiláctico de la disfunción sexual en mamíferos machos y hembras que comprende (6R-trans)-6-(1,3-benzodioxol-5-il)- 2,3,6,7,12,12a-hexahidro-2-me til-pirazino [1',2':1,6] pirido[3,4-b]indol-1,4-diona) o una sal o un solvato farmacéuticamente aceptables del mismo, junto con portadores farmacéuticamente aceptables.
MX2016002581A 2016-02-26 2016-02-26 Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5. MX2016002581A (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2016002581A MX2016002581A (es) 2016-02-26 2016-02-26 Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.
PCT/IB2017/000242 WO2017144973A2 (es) 2016-02-26 2017-02-17 Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5
CL2018002441A CL2018002441A1 (es) 2016-02-26 2018-08-24 Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016002581A MX2016002581A (es) 2016-02-26 2016-02-26 Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.

Publications (1)

Publication Number Publication Date
MX2016002581A true MX2016002581A (es) 2017-08-25

Family

ID=59684801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002581A MX2016002581A (es) 2016-02-26 2016-02-26 Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.

Country Status (3)

Country Link
CL (1) CL2018002441A1 (es)
MX (1) MX2016002581A (es)
WO (1) WO2017144973A2 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070067173A (ko) * 2005-08-29 2007-06-27 테바 파마슈티컬 인더스트리즈 리미티드 이정점 입도 분포를 갖는 고체 미립자 타달라필
WO2013109230A1 (en) * 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical compositions comprising tadalafil
IN2013MU01177A (es) * 2013-03-28 2015-04-17 Astron Res Ltd

Also Published As

Publication number Publication date
WO2017144973A3 (es) 2017-11-23
WO2017144973A2 (es) 2017-08-31
CL2018002441A1 (es) 2018-11-16

Similar Documents

Publication Publication Date Title
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
NZ766835A (en) Pharmaceutical compounds
MX2019001900A (es) Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxife nil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma.
MX2019013643A (es) Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona.
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
CL2012001329A1 (es) Procedimiento de purificacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo-[3,4-b]piridin-3-il] pirimidin-5-il} metilcarbamato de metilo; y el compuesto intermediario que se obtiene.
MX347359B (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2011156405A3 (en) Oral spray formulations and methods for administration of sildenafil
MX2020002711A (es) Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
WO2014027975A3 (en) Novel orally administered pharmaceutical formulations
PH12016502307A1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
MX2022001966A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
MX2021014674A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
MX367913B (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1.
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
WO2014027981A3 (en) Effervescent tablet formulations of dapoxetine and a pde5 inhibitor
MX2016002581A (es) Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.
NO20062883L (no) Fosfodiesterase-V-inhibitorpreparater